

Supplementary Table I. Cholesterol efflux assay validation

Batch	n plates/batch	ABDP	Cholesterol efflux C-	Real cholesterol efflux C+	n patients	replicates/n	intra-assay CV^s (between triplicates)	intra-batch CV[#] (inter-plate)
1	4	PL	7.4	22.8	24	triplicates	6.3 (0.8-11.7)	7.9 (7.9-8.0)
2	4	PL	8.6	21.5	24	triplicates	6.5 (0.9-15.6)	6.1 (4.8-7.4)
3	4	PL	8.0	24.7	24	triplicates	4.5 (0.9-12.9)	7.9 (3.4-12.3)
4	4	PL	7.4	26.2	24	triplicates	5.5 (1.2-10.6)	5.8 (4.0-7.5)
5	5	PL	7.3	20.7	28	triplicates	4.6 (1.4-8.4)	7.0 (5.4-8.6)
Total Study	21	PL	7.7±0.6^{&}	23.2±2.3^{&}	124	triplicates	5.5 (4.5-6.5)	6.9 (5.8-9.8)^z

ABDS/P, ApoB-depleted serum/plasma; PL, plasma; C-, negative control (no ABDP); positive control (ABDS from a pool of human plasma); CV, coefficient of variation; ^s Intra-assay CV is calculated as the average CV between triplicate values of cholesterol efflux of the same patient. [#] Intra-batch CV is determined as the CV of cholesterol efflux of the negative and positive control between plates in a batch. [&] Mean ± standard deviation. ^z Inter-batch CV assess the dispersion between positive control real cholesterol efflux values (column *Real cholesterol efflux C+*) among batches.